Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:INO
- CUSIP: N/A
- Web: www.inovio.com
Capitalization:- Market Cap: $625.37 million
- Outstanding Shares: 74,627,000
Average Prices:- 50 Day Moving Avg: $7.40
- 200 Day Moving Avg: $6.84
- 52 Week Range: $5.83 - $11.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.07
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $37.63 million
- Price / Sales: 16.62
- Book Value: $1.42 per share
- Price / Book: 5.90
Profitability:- EBIDTA: ($80,300,000.00)
- Net Margins: -235.91%
- Return on Equity: -65.97%
- Return on Assets: -48.95%
Debt:- Current Ratio: 2.67%
- Quick Ratio: 2.67%
Misc:- Average Volume: 1.50 million shs.
- Beta: 2.83
- Short Ratio: 4.32
Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals's stock reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.31) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.31). The business had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The business's revenue for the quarter was up 28.4% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share. View Inovio Pharmaceuticals' Earnings History.
Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?
9 brokerages have issued 12 month price objectives for Inovio Pharmaceuticals' shares. Their forecasts range from $11.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $22.11 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.
What are analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)
- 2. According to Zacks Investment Research, "Inovio reported narrower than expected loss in first quarter of 2017, with revenue beating estimates. Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Moreover, Inovio’s over-dependence on government grants and contracts for the development of its candidates is also concerning." (5/15/2017)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Genus plc (GNS), Esperion Therapeutics (ESPR), Immunomedics (IMMU), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Cara Therapeutics (CARA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX), CRISPR THERAPTC (CRSP), Mesoblast Limited (MESO), ImmunoGen (IMGN), Spectrum Pharmaceuticals (SPPI) and Intellia Therapeutics (NTLA).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
- Peter D. Kies, Chief Financial Officer
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer
- Mark L. Bagarazzi M.D., Chief Medical Officer
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
- George W. Bickerstaff III, Director
- David B. Weiner, Director
- Simon X. Benito, Independent Director
- Angel Cabrera Ph.D., Independent Director
Who owns Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.18%), State Street Corp (3.37%), Morgan Stanley (0.89%), Geode Capital Management LLC (0.76%), Bank of New York Mellon Corp (0.46%) and Schwab Charles Investment Management Inc. (0.41%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, State Street Corp, Goldman Sachs Group Inc., Alliancebernstein L.P., TIAA CREF Investment Management LLC, ProShare Advisors LLC and Bellevue Group AG. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner, Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.
Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Wells Fargo & Company MN, Vident Investment Advisory LLC, Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Metropolitan Life Insurance Co. NY. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy Inovio Pharmaceuticals stock?
Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $8.38.
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.78) |
| Consensus Price Target: | $22.11 (163.86% upside) |
Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/9/2017 | HC Wainwright | Reiterated Rating | Buy | $13.00 | Low |  |
| 6/8/2017 | Maxim Group | Set Price Target | Buy | $12.00 | High | |
| 6/8/2017 | Piper Jaffray Companies | Upgrade | Neutral -> Overweight | $14.00 | Medium | |
| 5/25/2017 | Aegis | Boost Price Target | Buy | $11.00 -> $14.00 | Low | |
| 5/25/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $11.00 | High | |
| 5/1/2017 | Nomura | Reiterated Rating | Buy | $40.00 | Low | |
| 5/1/2017 | Jefferies Group LLC | Reiterated Rating | Neutral | $38.00 | Low | |
| 5/1/2017 | BNP Paribas | Reiterated Rating | Neutral | $39.00 | Low | |
| 10/4/2016 | Brean Capital | Initiated Coverage | Buy | $18.00 | N/A | |
| 6/21/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $17.00 | N/A | |
(Data available from 6/27/2015 forward)
Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.31) | ($0.31) | $5.83 million | $10.40 million | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.29) | ($0.35) | $5.21 million | $8.50 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.26) | ($0.28) | $5.16 million | $12.54 million | View | Listen | |
| 8/8/2016 | Q2 | ($0.21) | ($0.26) | $4.95 million | $6.20 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.14) | ($0.11) | $4.75 million | $8.10 million | View | N/A | |
| 3/14/2016 | Q4 | ($0.20) | ($0.25) | $6.96 million | $5.94 million | View | Listen | |
| 11/9/2015 | Q3 | $0.04 | $0.07 | $1.84 million | $24.18 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.13) | ($0.10) | $5.52 million | $5.30 million | View | Listen | |
| 5/11/2015 | Q1 | ($0.11) | ($0.18) | $7.04 million | $5.20 million | View | Listen | |
| 3/16/2015 | Q414 | ($0.10) | ($0.12) | $5.24 million | $2.50 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.11) | ($0.12) | $5.60 million | $1.80 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.17) | ($0.19) | $1.80 million | $3.80 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.04) | ($0.05) | $1.41 million | $2.40 million | View | N/A | |
| 3/17/2014 | Q413 | ($0.03) | ($0.04) | $1.36 million | $1.70 million | View | N/A | |
| 11/11/2013 | Q3 | ($0.02) | ($0.16) | $2.99 million | $9.50 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.05) | ($0.05) | $2.07 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)Current Year EPS Consensus Estimate: $-1.10 EPS
Next Year EPS Consensus Estimate: $-1.38 EPS
Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 27.73%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | David B Weiner | Director | Sell | 8,000 | $8.00 | $64,000.00 | |
| 3/31/2017 | Jong Joseph Kim | CEO | Sell | 147,180 | $6.54 | $962,557.20 | |
| 3/27/2017 | Morton Collins | Director | Buy | 21,300 | $6.25 | $133,125.00 | |
| 8/29/2016 | Niranjan Sardesai | COO | Sell | 21,800 | $9.30 | $202,740.00 | |
| 6/28/2016 | Morton Collins | Director | Buy | 10,000 | $9.13 | $91,300.00 | |
| 5/18/2016 | Simon X Benito | Director | Sell | 6,250 | $10.37 | $64,812.50 | |
| 4/15/2016 | Morton Collins | Director | Buy | 68,400 | $9.52 | $651,168.00 | |
| 9/30/2015 | Niranjan Sardesai | COO | Buy | 4,000 | $5.50 | $22,000.00 | |
| 8/14/2015 | Simon X Benito | Director | Buy | 6,000 | $7.21 | $43,260.00 | |
| 4/13/2015 | Angel Cabrera | Director | Buy | 8,000 | $9.53 | $76,240.00 | |
| 10/9/2014 | Peter Kies | CFO | Buy | 3,960 | $10.10 | $39,996.00 | |
| 8/21/2014 | Morton Collins | Director | Buy | 8,000 | $10.01 | $80,080.00 | |
| 8/20/2014 | Morton Collins | Director | Buy | 40,600 | $9.74 | $395,444.00 | |
| 8/12/2014 | Jong Joseph Kim | CEO | Buy | 250,000 | $9.06 | $2,265,000.00 | |
| 8/12/2014 | Niranjan Sardesai | COO | Buy | 2,550 | $8.70 | $22,185.00 | |
| 4/15/2014 | Jong Joseph Kim | CEO | Buy | 25,000 | $2.25 | $56,250.00 | |
| 11/13/2013 | Morton Collins | Director | Buy | 254,500 | $1.82 | $463,190.00 | |
| 4/16/2013 | Mark Bagarazzi | Insider | Buy | 60,000 | $0.56 | $33,600.00 | |
| 4/2/2013 | Jong Joseph Kim | CEO | Buy | 90,000 | $0.50 | $45,000.00 | |
| 3/22/2013 | Angel Cabrera | Director | Buy | 40,000 | $0.54 | $21,600.00 | |
| 3/20/2013 | Jong Joseph Kim | CEO | Buy | 60,000 | $0.53 | $31,800.00 | |
| 3/20/2013 | Niranjan Sardesai | COO | Buy | 25,000 | $0.53 | $13,250.00 | |
| 1/15/2013 | Morton Collins | Director | Buy | 100,000 | $0.67 | $67,000.00 | |
| 11/14/2012 | Austin W & Greenhouse Da Marxe | Major Shareholder | Sell | 622,550 | $0.53 | $329,951.50 | |
| 8/15/2012 | Angel Cabrera | Director | Buy | 75,000 | $0.59 | $44,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
| Source: |
|
| Date | Headline |
|---|
 | Prostate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at RnRMarketResearch.com
www.prnewswire.com - June 22 at 11:12 PM |
 | Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 21 at 3:37 PM |
 | Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - GlobeNewswire (press release)
globenewswire.com - June 20 at 2:57 AM |
 | Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
finance.yahoo.com - June 19 at 12:21 PM |
 | Inovio Pharma (INO) Completes Enrollment for Second Zika Vaccine Phase 1 Trial with 160 Subjects in Puerto Rico
www.streetinsider.com - June 16 at 5:27 AM |
| Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
finance.yahoo.com - June 16 at 5:26 AM |
| Why Is Inovio (INO) Up 21.3% Since the Last Earnings Report?
finance.yahoo.com - June 14 at 11:22 AM |
 | Inovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 13 at 8:52 PM |
| 3 Stocks That Could Put Amazon's Returns to Shame
finance.yahoo.com - June 13 at 5:41 PM |
| Maxim Group Analysts Give Inovio Pharmaceuticals Inc (INO) a $12.00 Price Target
www.americanbankingnews.com - June 11 at 8:30 AM |
| $18.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - June 11 at 7:44 AM |
| Inovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - June 10 at 12:28 AM |
| Cramer’s Exec Cut: CEOs examine the power of strategic pa...
finance.yahoo.com - June 9 at 8:24 PM |
| Inovio Pharmaceuticals Inc (INO) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - June 9 at 7:38 PM |
| Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises
finance.yahoo.com - June 9 at 9:32 AM |
 | FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study - Benzinga
www.benzinga.com - June 8 at 11:58 PM |
 | Why Inovio Pharmaceuticals, Inc. Is Rising Today - Motley Fool
www.fool.com - June 8 at 11:58 PM |
| Inovio Pharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - June 8 at 11:58 PM |
| Biotech Movers: NewLink, Inovio, Juno
finance.yahoo.com - June 8 at 6:52 PM |
| Why Inovio Pharmaceuticals, Inc. Is Rising Today
finance.yahoo.com - June 8 at 6:52 PM |
| Inovio Pharmaceuticals Inc (INO) Upgraded to Overweight by Piper Jaffray Companies
www.americanbankingnews.com - June 8 at 12:22 PM |
| FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study
feeds.benzinga.com - June 8 at 11:46 AM |
| Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
finance.yahoo.com - June 8 at 6:07 AM |
 | Is Inovio Pharma's Zika Vaccine the Next Big Thing? - 24/7 Wall St.
247wallst.com - June 7 at 10:32 PM |
| These 2 Big Events Pushed Inovio Pharmaceuticals, Inc. Higher by 20% in May - Motley Fool
www.fool.com - June 7 at 10:32 PM |
 | BRIEF-Inovio Zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study
www.reuters.com - June 7 at 5:31 PM |
| These 2 Big Events Pushed Inovio Pharmaceuticals, Inc. Higher by 20% in May
www.fool.com - June 7 at 11:42 AM |
| Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
finance.yahoo.com - June 7 at 10:07 AM |
| Is Inovio Pharma’s Zika Vaccine the Next Big Thing?
finance.yahoo.com - June 7 at 10:07 AM |
| ETFs with exposure to Inovio Pharmaceuticals, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 5:57 PM |
| Inovio Pharmaceuticals Inc (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - June 4 at 11:46 PM |
| Inovio Pharmaceuticals Inc (INO) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 11:14 AM |
| Inovio, Roche Enter Into Clinical Collaboration For Advanced Bladder Cancer
www.nasdaq.com - June 1 at 11:45 PM |
| BRIEF-Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor
www.reuters.com - June 1 at 11:45 PM |
| Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 ... - GlobeNewswire (press release)
www.globenewswire.com - June 1 at 6:45 PM |
| Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor
finance.yahoo.com - June 1 at 6:45 PM |
| Inovio Pharmaceuticals Inc (INO) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - June 1 at 1:40 PM |
| Inovio Pharmaceuticals Inc (INO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 28 at 7:20 AM |
| David B. Weiner Sells 8,000 Shares of Inovio Pharmaceuticals Inc (INO) Stock
www.americanbankingnews.com - May 26 at 8:02 PM |
| Inovio Shares Rise And Fall Like A Roller Coaster
finance.yahoo.com - May 26 at 6:39 PM |
| Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
finance.yahoo.com - May 26 at 6:39 PM |
| ETFs with exposure to Inovio Pharmaceuticals, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 6:39 PM |
| Inovio's HIV Vaccine Elicits High Response Rates In Phase 1 Trial
www.benzinga.com - May 26 at 2:26 AM |
 | Prepare For More Dilution Of Inovio Pharmaceuticals
seekingalpha.com - May 26 at 2:26 AM |
| Inovio Pharmaceuticals' (INO) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - May 26 at 12:58 AM |
| Inovio Surrenders Some Early Gains After Positive HIV Vaccine Clinical Study
www.benzinga.com - May 24 at 10:53 PM |
 | Where Might Inovio Shares Land Post-Breakout? (INO)
www.investopedia.com - May 24 at 5:51 PM |
| Why Inovio Pharmaceuticals May Be the Next Big Thing
finance.yahoo.com - May 24 at 5:51 PM |
| Where Might Inovio Shares Land Post-Breakout?
finance.yahoo.com - May 24 at 5:51 PM |
| Inovio Pharmaceuticals Inc (INO) Price Target Raised to $12.00
www.americanbankingnews.com - May 24 at 3:20 PM |
Inovio Pharmaceuticals (INO) Chart for Tuesday, June, 27, 2017
